Seagen to Showcase Data from Growing Oncology Portfolio During Virtual Scientific Program of the 2021 ASCO Annual Meeting

Rhea-AI Summary

Seagen Inc. (Nasdaq:SGEN) announced new data from its pipeline of therapies at the virtual ASCO Annual Meeting, held June 4-8, 2021. Key highlights include updated results from the EV-103 and EV-201 clinical trials for PADCEV® in urothelial cancer and data from the HER2CLIMB trial of TUKYSA® in HER2+ metastatic breast cancer. Chief Medical Officer Roger Dansey emphasized progress in the company's oncology portfolio, addressing a high unmet need across multiple cancers.

Positive

• Presentation of new data from two pivotal clinical trials, EV-103 and EV-201, enhances PADCEV's market positioning.
• Demonstrating ongoing advancement in the oncology pipeline, potentially leading to increased investor confidence.

Negative

• None.

Seagen Inc. (Nasdaq:SGEN) today announced the presentation of new data from its growing pipeline of marketed and investigational therapies at the virtual scientific program of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 4-8.

“Emerging data and the breadth of our clinical development programs continue to illustrate progress across our oncology portfolio, highlighting the company’s research efforts in multiple cancers with a high unmet need,” said Roger Dansey, M.D., Chief Medical Officer at Seagen. “Notably, we are looking forward to sharing updated results of the EV-103 and EV-201 clinical trials for PADCEV® (enfortumab vedotin-ejfv) in locally advanced or metastatic urothelial cancer and additional data from the HER2CLIMB trial of TUKYSA® (tucatinib) in previously treated HER2+ metastatic breast cancer patients.”

Key data to be presented include:

Abstract Title	Abstract #	Presentation type	Lead Author
PADCEV® (enfortumab vedotin-ejfv)
Study EV-103: Update on durability results and long-term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC)	4528	Poster Presentation	T. Friedlander
Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2	4524	Poster Presentation	B. McGregor
Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized Phase 3 trial of enfortumab vedotin vs chemotherapy	4539	Poster Presentation	R. Mamtani
KEYNOTE-B15/EV-304: Randomized Phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC)	TPS4587	Poster Presentation	C. Hoimes

FAQ

What new data is Seagen presenting at ASCO 2021?

Seagen is presenting new data from EV-103 and EV-201 clinical trials for PADCEV® and additional data from the HER2CLIMB trial for TUKYSA®.

When is the ASCO Annual Meeting where Seagen is presenting?

The ASCO Annual Meeting is being held virtually from June 4-8, 2021.

What is the focus of Seagen's presentation at ASCO?

Seagen's presentation focuses on advancements in its oncology portfolio, particularly addressing high unmet needs in cancer treatment.

Which therapies are highlighted in Seagen's ASCO presentation?

The therapies highlighted include PADCEV® (enfortumab vedotin) and TUKYSA® (tucatinib).

Who is the Chief Medical Officer of Seagen?

Roger Dansey, M.D., is the Chief Medical Officer of Seagen.